Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106


Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.

Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK.

J Surg Oncol. 2019 Dec;120(8):1311-1317. doi: 10.1002/jso.25727. Epub 2019 Oct 15.


Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.

Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J.

Ann Oncol. 2019 Oct 1;30(10):1622-1629. doi: 10.1093/annonc/mdz287.


High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.

Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS.

PLoS One. 2019 Jul 10;14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.


RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P.

JCI Insight. 2019 Jun 25;5. pii: 127552. doi: 10.1172/jci.insight.127552.


Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.

Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS.

Transl Oncol. 2019 Mar;12(3):550-560. doi: 10.1016/j.tranon.2018.12.007. Epub 2019 Jan 9.


Discontinuities in soil strength contribute to destabilization of nutrient-enriched creeks.

Wigand C, Watson EB, Martin R, Johnson DS, Warren RS, Hanson A, Davey E, Johnson R, Deegan L.

Ecosphere. 2018 Aug;9(8):e02329. doi: 10.1002/ecs2.2329.


A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK.

Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.


Sampling strategies to capture single-cell heterogeneity.

Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ.

Nat Methods. 2017 Oct;14(10):967-970. doi: 10.1038/nmeth.4427. Epub 2017 Sep 4.


Anthropocene survival of southern New England's salt marshes.

Watson EB, Raposa KB, Carey JC, Wigand C, Warren RS.

Estuaries Coast. 2017 May 1;40(3):617-625. doi: 10.1007/s12237-016-0166-1.


Contrasting decadal-scale changes in elevation and vegetation in two Long Island Sound salt marshes.

Carey JC, Raposa KB, Wigand C, Warren RS.

Estuaries Coast. 2017 May 1;40(3):651-661. doi: 10.1007/s12237-015-0059-8.


Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.


Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.


Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.


A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.


Saltmarsh plant responses to eutrophication.

Johnson DS, Warren RS, Deegan LA, Mozdzer TJ.

Ecol Appl. 2016 Dec;26(8):2647-2659. doi: 10.1002/eap.1402. Epub 2016 Oct 20.


Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.


Unexpected insights for anti-EGFR cancer therapy.

Depeille P, Warren RS, Roose JP.

Oncotarget. 2015 Aug 7;6(22):18746-7. No abstract available.


CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology.

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009. Epub 2014 May 21.


PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.

Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS.

Cancer Med. 2013 Aug;2(4):496-506. doi: 10.1002/cam4.97. Epub 2013 Jun 10.


Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.

J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.


Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM.

Clin Cancer Res. 2013 Oct 15;19(20):5777-87. doi: 10.1158/1078-0432.CCR-13-0351. Epub 2013 Aug 27.


Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.


Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM.

J Clin Oncol. 2013 May 10;31(14):1775-81. doi: 10.1200/JCO.2012.45.1096. Epub 2013 Mar 25.


Imaging a functional tumorigenic biomarker in the transformed epithelium.

LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8. doi: 10.1073/pnas.1218694110. Epub 2012 Dec 17.


Coastal eutrophication as a driver of salt marsh loss.

Deegan LA, Johnson DS, Warren RS, Peterson BJ, Fleeger JW, Fagherazzi S, Wollheim WM.

Nature. 2012 Oct 18;490(7420):388-92. doi: 10.1038/nature11533.


Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.

Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK.

Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0.


Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM.

Invest New Drugs. 2012 Dec;30(6):2219-25. doi: 10.1007/s10637-012-9793-y. Epub 2012 Jan 24.


Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.

Venook AP, Bendell JC, Warren RS.

Am Soc Clin Oncol Educ Book. 2012:193-200. doi: 10.14694/EdBook_AM.2012.32.193.


Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.

Tseng WW, Wang SC, Eichler CM, Warren RS, Nakakura EK.

World J Surg Oncol. 2011 Nov 4;9:143. doi: 10.1186/1477-7819-9-143.


Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS.

J Clin Oncol. 2011 Aug 10;29(23):3153-62. doi: 10.1200/JCO.2010.33.0092. Epub 2011 Jul 11.


Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB 3rd, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA.

J Clin Oncol. 2011 Aug 10;29(23):3146-52. doi: 10.1200/JCO.2010.32.5357. Epub 2011 Jul 11.


Pancreatic adenocarcinoma.

Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma.

J Natl Compr Canc Netw. 2010 Sep;8(9):972-1017. No abstract available.


Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.

Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, Castro AF.

Oncogene. 2010 Dec 16;29(50):6543-56. doi: 10.1038/onc.2010.393. Epub 2010 Sep 6.


Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.

Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

J Surg Res. 2010 Sep;163(1):47-51. doi: 10.1016/j.jss.2010.04.018. Epub 2010 May 6.


Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK.

Arch Surg. 2010 Mar;145(3):276-80. doi: 10.1001/archsurg.2010.10.


The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.

Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2010 Feb 18;17(1):283-91. doi: 10.1677/ERC-09-0243. Print 2010 Mar.


p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.

Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M.

Clin Cancer Res. 2009 Mar 15;15(6):2116-22. doi: 10.1158/1078-0432.CCR-08-2674. Epub 2009 Mar 10.


Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.

J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.


Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.

Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E.

Surgery. 2008 Dec;144(6):908-13; discussion 913-4. doi: 10.1016/j.surg.2008.07.028.


Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.

Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2009 Mar;16(1):267-79. doi: 10.1677/ERC-08-0127. Epub 2008 Nov 5.


Association of family history with cancer recurrence and survival among patients with stage III colon cancer.

Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS.

JAMA. 2008 Jun 4;299(21):2515-23. doi: 10.1001/jama.299.21.2515.


Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.

Guo L, Clark JP 3rd, Warren RS, Nakakura EK.

Ann Surg Oncol. 2008 Jun;15(6):1594-9. doi: 10.1245/s10434-008-9903-4. Epub 2008 Apr 12.


Prognostic importance of superior diaphragmatic adenopathy at computed tomography in patients with resectable hepatic metastases from colorectal carcinoma.

Aslam R, Coakley FV, Williams G, Yeh BM, Joe BN, Zuraek MB, Warren RS.

J Comput Assist Tomogr. 2008 Mar-Apr;32(2):173-7. doi: 10.1097/RCT.0b013e3181570370.



Warren RS, Nakakura EK.

Surg Oncol. 2007 Dec;16(4):235. Epub 2007 Nov 26. No abstract available.


Palliative care for patients with advanced pancreatic and biliary cancers.

Nakakura EK, Warren RS.

Surg Oncol. 2007 Dec;16(4):293-7. Epub 2007 Sep 14. Review.


Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD.

Cancer Res. 2007 Jan 15;67(2):450-4.


Pancreatoblastoma in an adult: case report and review of the literature.

Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK.

J Gastrointest Surg. 2006 Jun;10(6):829-36. Review.


Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation.

Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA, Warren RS, Ferrell L.

Cancer Gene Ther. 2006 Aug;13(8):792-7. Epub 2006 Apr 21.


Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ.

J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.


[Liver metastases from colorectal cancer. Is the practice of surgery based on the best clinical evidence possible?].

Durán Giménez-Rico H, García-Aguilar J, Warren RS, Iborra P, Guerrero V.

Cir Esp. 2005 Aug;78(2):75-85. Review. Spanish.

Supplemental Content

Loading ...
Support Center